D Wave Quantum Inc vs Smith & Nephew plc — how do they compare? D Wave Quantum Inc trades at $17.32 (market cap $6.58B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.85% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| QBTS | SNN | |
|---|---|---|
Market Cap | $6.58B | $11.63B |
Sector | Technology | Health |
52-Week High | $44.78 | $38.53 |
52-Week Low | $12.98 | $27.80 |
Enterprise Value | $6.08B | $14.66B |
Dividend Yield | — | 2.85% |
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $17.67, up 6.57% in the last session, but remains down 33% year-to-date. The stock shows a bearish technical trend with key support at $17 and resistance at $18. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million in revenue for 2025, with a negative net income margin of -2,001.59% in 2026. Recent positive news includes a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS Act, announced on September 8, 2026.
Despite unanimous analyst buy ratings and a $37.00 consensus price target, significant execution risks persist. High cash burn, negative profitability, and ongoing SEC investigations pose challenges. The stock's upside depends on successful commercialization of quantum technology and effective use of government funding, but near-term volatility is expected amid sector-wide pressures and macroeconomic uncertainty.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →